These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8342323)

  • 1. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses.
    Wills MR; Singh BK; Debnath NC; Barrett AD
    Vaccine; 1993; 11(7):761-6. PubMed ID: 8342323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area.
    Wills MR; Sil BK; Cao JX; Yu YX; Barrett AD
    Vaccine; 1992; 10(12):861-72. PubMed ID: 1455912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of experimental live attenuated Japanese encephalitis vaccine viruses and comparison with wild-type strains using monoclonal and polyclonal antibodies.
    Sil BK; Wills MR; Cao JX; Sharda R; Islam MA; Stagg DJ; Jennings AD; Gibson CA; Barrett AD
    Vaccine; 1992; 10(5):329-33. PubMed ID: 1315470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2.
    Lee T; Komiya T; Watanabe K; Aizawa C; Hashimoto H
    Acta Virol; 1995 Jun; 39(3):161-4. PubMed ID: 8578998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.
    Gromowski GD; Firestone CY; Whitehead SS
    J Virol; 2015 Jun; 89(12):6328-37. PubMed ID: 25855730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone.
    Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y
    Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2.
    Yang D; Li XF; Ye Q; Wang HJ; Deng YQ; Zhu SY; Zhang Y; Li SH; Qin CF
    Vaccine; 2014 May; 32(23):2675-81. PubMed ID: 24709585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children.
    Xin YY; Ming ZG; Peng GY; Jian A; Min LH
    Am J Trop Med Hyg; 1988 Aug; 39(2):214-7. PubMed ID: 2841880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.
    Gromowski GD; Firestone CY; Bustos-Arriaga J; Whitehead SS
    Am J Trop Med Hyg; 2015 Jan; 92(1):98-107. PubMed ID: 25311701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants.
    Sohn YM; Park MS; Rho HO; Chandler LJ; Shope RE; Tsai TF
    Vaccine; 1999 May; 17(18):2259-64. PubMed ID: 10403593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
    Konishi E; Yamaoka M; Kurane I; Mason PW
    Virology; 2000 Mar; 268(1):49-55. PubMed ID: 10683326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice.
    Cao JX; Ni H; Wills MR; Campbell GA; Sil BK; Ryman KD; Kitchen I; Barrett AD
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2757-64. PubMed ID: 7595383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.